ASH 2023 | Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler
• 9 Dec 2023
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses a longitudinal study investigating trends in allogeneic stem cell transplantation (alloSCT) in the treatment of good-risk acute myeloid leukemia (AML). The study found that in recent periods, there have been changes in the demographic of patients undergoing alloSCT, a reduction in non-relapse mortality (NRM) and graft-versus-host disease (GvHD), but no difference in overall survival (OS) and leukemia-free survival (LFS). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
